Neuroendocrine differentiation in prostatic malignancy is receiving considerable attention; this occurs commonly as a “focal” histological variant and, most rarely, in the form of small cell carcinoma (“oat cell carcinoma”) and carcinoid tumor. In prostate cancer, neuroendocrine differentiation may be the response to androgen deprivation and neuroendocrine products, either biogenic amines or peptides, have been shown to stimulate proliferation of androgen-ablation refractory cancer cells. Serum chromogranins, neuron-specific enolase and other neuroendocrine products as well as 111-In-chromogranin A “three step” immunoscintigraphy and somatostatin-receptor scintigraphy may be useful for predicting tumor behaviour and patient prognosis.
Several of the neuroendocrine products, particularly somatostatin analogues, are candidates for new therapeutic approaches. The paper aims to outline the advances in this field on the basis of the review of the literature.
Di Sant'AgneseP., CockettA.T.. Neuroendocrine differentiation in prostatic malignancy.Cancer1996; 78: 357–61.
2.
AbrahamssonP.A.. Neuroendocrine differentiation in prostatic carcinoma.Prostate1999; 39: 135–48.
3.
HelapB., KollermanJ., OehlerU.. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance and future therapeutic perspectives.Urol Int1999; 62: 133–8.
4.
PretlK., Zur Frage der Endokrine der menshlichen vorsteherdruse.Virchows Arch Path Anat1944; 312: 392–404.
5.
CohenH., GlezersonG., TaylorL., GrundleH., NaudeJ.. The neuroendocrine cell population of the human prostate gland.J Urol1993; 150: 365–8.
6.
BattagliaS., CasaliA.M., BotticelliA.R.. Age-related distribution of endocrine cells in the human prostate; a quantitative study.Virchows Arch A.1994; 424: 165–8.
7.
Di Sant'AgneseP.A., de Mesey JensenK.L.. Endocrine-paracrine cells of the prostate and prostatic urethra: an ultra-structural study.Hum Pathol1984; 15, 1034–40.
8.
XueY., SmedtsF., VerhofstadA., DebruyneP., de La RosetteJ., SchalkenJ.. Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: new perspectives.Prostate1998; 8(suppl.): S62–70.
9.
FeyrterF.. Uber das urogenitale Helle-Zellen-System der Menschen.Mikr Anat Forsch1951; 57: 324–44.
10.
BonkhoffH., RembergerK.. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.Prostate1996; 28; 98–106.
11.
Van LeendersG.J., SchalkenJ.A.. Stem cell differentiation within human prostate epithelium: implications for prostate carcinogenesis.BJU Int2001; 88(suppl.): S435–42.
IwamuraM., KoshibaK., CockettA.T.. Receptors for benigne prostatic hyperplasia are located in some neuroendocrine cells.Prostate1998; 8: 14–17.
14.
BonkhoffH., WeinertN., DhomG., RembergerK.. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic and neoplastic human prostate.Prostate1991; 19: 91–9.
15.
NakadaS.Y., di Sant'AgneseP.A., MoynesR.A., HipakkaR.A., CockettA.J., AbrahamssonP.A.. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.Cancer Res1993; 53: 1967–70.
16.
GuyL., BeginL.R., OthmanK., ChevalierS., AprikianA.G.. Neuroendocrine cells of the veru montanum: comparative immunohistochemical study.BJU1998; 82: 738–43.
17.
YashiM., IshikawaS., OchiM., TokueA.. Small cell-neuroendocrine carcinoma may be more a phenotype in advanced prostate cancer.Urol Int2002; 69: 166–8.
18.
CubillanaP.L., BarbaE.M., PrietoA., PastorG.S., SolaJ., NicolasJ.A.. Oat-cell carcinoma of the prostate: diagnosis, prognosis and therapeutic implications.Urol Int2001; 67: 209–12.
19.
MiyoshiY., UemiaH., KitamiK., SatomiY., KrrbotaY., HosakaM.. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy.BJU Int2001; 88: 982–83.
AbrahamssonP.A.. Neuroendocrine cells in tumor growth of the prostate. Endocr. Relat.Cancer1999; 6: 503–9.
25.
HelpapB., KollermannJ.. Undifferentiated carcinoma of the prostate with small cell features.Virchows Arch A1999; 434: 385–90.
26.
RoJ.Y., TetuB., AyalaA.G.. Small cell carcinoma of the prostate.Cancer1987; 59: 977–82.
27.
CohenR.J., GlezersonG.. Prostate-specific antigen and acid phosphatase in neuroendocrine cells of prostate cancer.Arch Pathol Lab Med1992; 116: 65–71.
28.
De MarroA.M., NlesonW.G., MeekerA.K., CoffeyD.S.. Stem cell features of benign and malignant prostate epithelial cells.J Urol1998; 160: 2381–92.
29.
PruneriG.. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy.Prostate1998; 34: 113–120.
30.
BerrutiA.. Circulating neuroendocrine markers in patients with prostate carcinoma.Cancer2000; 88: 2590–7.
TetuB., RoJ.K., AjalaA.C., OrdonezN.G., LogothetisC.J., von FischenbachA.C.. Small cell. carcinoma of the prostate associated with myastenic (Eaton-Lambert) syndrome.Urology1989; 33: 148–52.
34.
IwamuraM., WuG., AbrahamssonP.A., di Sant'AgneseP.A., CockettA.T., DeftosL.J.. PTHrP is expressed by prostatic neuroendocrine cells.Urology1994; 43: 667–73.
35.
AlbertiC., TizzaniA.. Patologia metastatica ossea da carcinoma della prostata.Minerva Urol Nefrol2003; 55: 147–55.
36.
IwamuraM., HellmanJ., CockettA.T., LiljaH., GershagenS.. Alteration of the hormonal bioactivity of PTHrP as a result of limited proteolysis by PSA.Urology1996; 48: 317–25.
37.
CramerS.D., ChenZ., PeehlD.. Prostate specific antigen cleaves PTHrP in the the PTH-like domain.J Urol1996; 156: 526–30.
38.
BolognaM., FestucciaC., MuziP., BiordiL., CiomeiM.. Bombesin stimulates growth of human prostatic cancer cells in vitro.Cancer1989; 63: 1714–20.
39.
RozengutE., Sinnett-SmithJ.. Early signals underlying of c-fos and c-myc genes in quiescent fibroblasts: studies with bombesin and other growth factors.Prog Nucl Acid Res Mol Biol1988; 35: 261–95.
40.
JuliusD., LivelliT.J., JesselT.M., AxelR.. Ectopic expression of the serotonin 1C receptor and the triggering of malignant transformation.Science1989; 244: 1057–62.
41.
SeuwenK., PouyssegurJ.. Serotonin as a growth factor.Biochem Pharmacol1990; 39: 985–90.
42.
PollakM.N., SchallyA.V.. Mechanisms of antineoplastic action of somatostatin analogs.Proc Soc Exp Biol Med1998; 217: 143–52.
43.
HooseinN.M., LogothesisC.J., ChungL.W.. Differential effects of peptide hormones bombesin, VIP and somatostatin analog RC-160 on the invasive capacity of the human prostatic carcinoma cells.J Urol1993; 149: 1209–377.
44.
DaiJ., ShenR., SumitomoM., GoldbergJ.S., GengY., NavarroD.. Tumor-suppressive effects of neutral endopeptidase in androgen-indipendent prostate cancer cells.Clin Cancer Res2001; 7: 1370–77.
45.
PapandreuC.N., UsmaniB., GengY., BogenriederT., FreemanR., WilkS.. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-indipendent prostate cancer progression.Nat Med1998; 4: 50–7.
46.
FredlandS.J., SekigsonD.B., LiuA.Y., PantuckA.J., PaikS.H.. Loss of CD10–neutral endopeptidase is a frequent and early event in human prostate cancer.Prostate2003; 55: 71–80.
47.
CleggN, FergusonC, TrueLD, ArnoldH, MoormanA, QuinnJE. Molecular characterization of prostatic small cell neuroendocrine carcinoma.Prostate2003; 55: 55–64.
48.
McWilliamL.J., MansonC., GeorgeN.J.. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma.BJU1991; 80: 287–90.
49.
CohenR.J., GlezersonG., HaffajeeZ.. Neuroendocrine differentiation cells: a new prognostic parameter in prostate cancer.BJU1991; 68: 258–62.
50.
WeinsteinM.H., PartinA.W., VeltriR.W., EpsteinJ.I.. Neuroendocrine differentiation in prostate cancer: enhanced prediction and progression.Hum Pathol1996; 27: 683–90.
51.
Di Sant'AgneseP.A.. Neuroendocrine differentiation in carcinoma of the prostate: diagnostic, prognostic, therapeutic implications.Cancer1992; 70: 254–60.
SegalN.H., CohenR.J., HaffejeZ., SavageN.. Bcl-2 protoncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cells.Arch Pathol Lab Med1994; 118: 616–8.
54.
AmbrosiniG., AdidaC., AltieriD.C.. A novel antiapoptosis gene, survivin, expressed in cancer lymphoma.Nat Med1997; 3: 917–21.
55.
XingN., QuianJ., BostwickD., BergstrainE., YoungC.Y.. Neuroendocrine cells in human prostate overexpress the anti-apoptosis protein survivin.Prostate2001; 48: 7–15.
56.
CornetA.M., HenonE., ReiterE.R., BruyninxM., NguyenV.N., HennuyB.R.. Prostatic androgen repressed mes-sage-1 (PARM-1) may play a role in prostatic cell immortalization.Prostate2003; 56: 220–230.
57.
MazzucchelliR., MontironiR., SantinelliA., LucariniG., PugnaloniA., BiaginiG.. VEGF expression and capillary architecture in PIN-HG and prostate cancer in untreated and androgen-ablated patients.Prostate2000; 45: 72–9.
58.
Di SilverioF., SciarraA.. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases Chromogranin-A in patients with androgen ablation refractory prostate cancer.J Urol2003; 170: 110–17.
59.
AngelsenA., SyeversenU., StrdsbergH., HaugenO.A., HjohnerodO.K., WaldumH.. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.Prostate1997; 31: 110–17.
60.
WuJ.T., AstillM.E., LiuG.H., StephensonB.A.. Serum chromogranin-A early detection of hormonal resistance in prostate cancer patients.J Clin Lab Anal1998; 12: 20–8.
61.
CussenotO., VilletteJ.M., Cochand-PriolletB., BerthonP.. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumours.Prostate1998; 8(suppl.): S43–51.
62.
LillelyW., PausE., SkovlundE., FossaS.D.. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.Prostate2001; 46: 126–133.
HaraT., KosakaN., KishiH.. PET imaging of prostate cancer using 11-C-choline.J Nucl Med1998; 39: 990.
73.
NarayanP., JajodiaP., KurhanewiczJ.. Characterization of prostate cancer, BPH and normal prostate using 31P-magnetic resonance spectroscopy.J Urol1991; 146: 66–71.
ÖbergK.. Interferon in the management of neuroendocrine-GEP-tumors.Digestion2000; 62(Suppl 1): S92–7.
76.
KoppanM., NagyA., SchallyA.V., ArencibiaJ.M., PlonowskiA., HalmosG.. Targeted cytotoxic analog of somatostatin AN-238 inhibits growth of androgen-indipendent Dunning R-3327-AT-1 prostate cancer in rats at non toxic doses.Cancer Res1998; 58: 4132–7.
77.
MahmouldS., StameyJ., TaylorJ., BogdenA., MoreauJ.P., CoyD.. Bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo.Cancer Res1991; 51: 1798–802.
78.
AbdulM., AnezinisP.E., LogothetisC.J., HooseinN.M.. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists.Anticancer Res1994; 14: 1215–20.
79.
ReubiJ.C., WaserB., SchaerJ.C., MarkwalderR.. Somatostatin receptors in human prostate and prostate cancer.J Clin Endocrinol Metab1995; 80: 2806–14.
80.
NilssonS., ReubiJ.C., KalknerK.M., LaissueJ.A., HorisbergerU., OlerudC.. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by 111In-labeled DTPA-octreotide scintigraphy.Cancer Res1995; 55(suppl.): S5805–10.
81.
BarcenaD.G., SchallyA.V., BuehfilM.V., MoralesA.C., HernandezV., Cornejo-CardenasI.. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.Prostate2003; 56: 183–91.
82.
SchallyA.V., Comaru-SchallyA.M., PlonowskiA., NagyA., HalmosG., RekasiZ.. Peptide analogs in the therapy of prostate cancer.Prostate2000; 45: 158–66.
83.
SchallyA.V., ReddingT.W.. Somatostatin analogs as adjuncts to agonist of LH-RH in the treatment of experimental prostate cancer.Proc Natl Acad Sci USA,1987; 84: 7275–9.
84.
KoutsierisM., MitsiadesC., DimopoulosT., IoannidisA., NtounisA., LambouT.. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LH-RH analog in androgen ablation-refractory prostate cancer patients.J Clin Endocrinol Metab2001; 86: 5729–36.
85.
SciarraA., MariottiG., GentileV., VoriaG., PastoreA., MontiS., Di SilverioF.. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?BJU Int2003; 91: 438–45.
86.
ScherH.I., SarkisA., ReuterV.. Changing pattern of expression of the EGF-R and TGF-(in the progression of prostatic neoplasms).Clin Cancer Res1995; 1: 545–50.
87.
BerrutiA., DogliottiL., MoscaA., TarabuzziR., TortaM., MariM.. Effect of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, PSA and IGF-1 in advanced prostate cancer patients.Prostate2001; 47: 205–11.
88.
AlbertiC.. Tumori neuroendocrini: elementi d'interesse per l'urologo.Urol prat1998; 3: 95–105.
89.
AlbertiC.. Tumori neuroendocrini: crescente attenzione alla patologia neoplastica neuroendocrina della prostata.Riv It Biol Med2002; 22: 8–18.
90.
NelsonJ.B., CarducciM.A.. Small bioactive peptide and cell surface peptidase in androgen-indipendent prostate cancer.Cancer Invest2000; 18: 87–96.
91.
SchifferC.A.. Signal transduction inhibition, changing paradigms in cancer.Semin Oncol2001; 28: 34–39.
92.
van der PoelH.G.. Smart drugs in prostatic cancer.Eur Urol2004; 45: 1–17.
93.
YuJ., ZhangL.. Apoptosis in human cancer cells.Curr Opin Oncol2004; 16: 19–24.
